Venous Sinus Stenting for Pulsatile Tinnitus: A Systematic Review and Meta-Analysis.

Otol NeurotolJul 20, 2026 (epub)
Clinical ResearchNeurologyOtolaryngology (ENT)

Sevda Alipour Khabir, Julien Ognard, Gerard El Hajj et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of venous sinus stenting (VSS) for treating pulsatile tinnitus (PT) in 850 patients, including those with idiopathic intracranial hypertension (IIH). The study found a pooled rate of overall PT improvement of 89.8% and complete resolution in 87.1%. Recurrence was noted in 10.9% of cases.

Key findings

  • Pooled rate of overall PT improvement was 89.8% (95% CI, 85.5-92.9).
  • Complete resolution of PT occurred in 87.1% (95% CI, 82.5-90.6).
  • Recurrence rate at last follow-up was 10.9% (95% CI, 8.3-14.2).
  • Recurrence was higher in IIH (12.0%) compared to isolated PT (5.7%).

Why it matters

The findings highlight the effectiveness of VSS in managing pulsatile tinnitus, particularly in patients with venous sinus stenosis. Understanding the outcomes can guide clinicians in treatment decisions and patient counseling regarding expectations and potential recurrence.

Source

PubMed · PMID 42476523

Published in Otol Neurotol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.